UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overview of current systemic management of EGFR-mutant NSCLC

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i3-i9

2018

Volltextzugriff (PDF)

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S152-S152

2016

Volltextzugriff (PDF)

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

European journal of cancer (1990), 2014-05, Vol.50, p.e27-e27

2014

Volltextzugriff (PDF)

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S11-S11

2013

Volltextzugriff (PDF)

P1.22-21 Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S254-S255

2023

Volltextzugriff (PDF)

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Volltextzugriff (PDF)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Annals of oncology, 2017-02, Vol.28 (2), p.270-277

2017

Volltextzugriff (PDF)

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Annals of oncology, 2019-02, Vol.30 (2), p.171-210

2019

Volltextzugriff (PDF)

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Annals of oncology, 2018-03, Vol.29 (3), p.687-693

2018

Volltextzugriff (PDF)

P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S389-S390

2024

Volltextzugriff (PDF)

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Annals of oncology, 2016-11, Vol.27 (11), p.2103-2110

2016

Volltextzugriff (PDF)

384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)

Annals of oncology, 2022-11, Vol.33, p.S1591

2022

Volltextzugriff (PDF)

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

Annals of oncology, 2022-11, Vol.33, p.S1564-S1564

2022

Volltextzugriff (PDF)

Treatment of NSCLC Patients with EGFR Mutation

Annals of oncology, 2012-10, Vol.23, p.xi29

Yang, J.C.-H.

2012

Volltextzugriff (PDF)

1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

Annals of oncology, 2023-10, Vol.34, p.S848-S849

2023

Volltextzugriff (PDF)

P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S246-S247

2024

Volltextzugriff (PDF)

514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2

Annals of oncology, 2023-11, Vol.34, p.S1669-S1670

2023

Volltextzugriff (PDF)

185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S798-S798

2021

Volltextzugriff (PDF)

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

Annals of oncology, 2019-11, Vol.30, p.ix181

2019

Volltextzugriff (PDF)

1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations

Annals of oncology, 2024-09, Vol.35, p.S867-S867

2024

Volltextzugriff (PDF)

EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S463

2022

Volltextzugriff (PDF)

EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S350

2022

Volltextzugriff (PDF)

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-11, Vol.34, p.S1684-S1685

2023

Volltextzugriff (PDF)

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

Annals of oncology, 2023-11, Vol.34, p.S1661

2023

Volltextzugriff (PDF)

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

Annals of oncology, 2020-11, Vol.31, p.S1396-S1396

2020

Volltextzugriff (PDF)

1 – 25 von 146

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(146)

Publikationsform

Artikel
(146)

Sprache

Englisch
(146)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(14)
Humans
(13)
Oncology
(13)
Female
(8)
Male
(8)
Lung Neoplasms - Genetics
(7)
Aged
(6)
Carcinoma, Non-Small-Cell Lung - Genetics
(6)
Erbb Receptors - Genetics
(6)
Lung Neoplasms - Drug Therapy
(6)
Middle Aged
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Lung Neoplasms - Pathology
(5)
Mutation
(5)
Nsclc
(5)
Adult
(4)
Original Research
(4)
Afatinib
(3)
Antineoplastic Agents - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(10)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Overview of current systemic management of EGFR-mutant NSCLC

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

P1.22-21 Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

Treatment of NSCLC Patients with EGFR Mutation

1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2

185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations

EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

Suchergebnisse filtern